Brokerages Set Axon Enterprise, Inc (NASDAQ:AXON) PT at $805.71

Axon Enterprise, Inc (NASDAQ:AXON) has been given an average rating of “Moderate Buy” by the eighteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $805.7143.

A number of research firms recently weighed in on AXON. Barclays lowered their price target on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target for the company in a research report on Tuesday, January 6th. Morgan Stanley cut their price target on Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Finally, UBS Group decreased their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th.

Axon Enterprise Trading Up 3.6%

NASDAQ:AXON opened at $414.20 on Wednesday. Axon Enterprise has a 1 year low of $396.41 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. The stock has a fifty day moving average price of $568.26 and a two-hundred day moving average price of $657.85. The stock has a market capitalization of $32.68 billion, a price-to-earnings ratio of 131.08, a PEG ratio of 12.48 and a beta of 1.48.

Insiders Place Their Bets

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $550.63, for a total transaction of $55,063.00. Following the sale, the director owned 1,316 shares in the company, valued at approximately $724,629.08. This represents a 7.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Brittany Bagley sold 2,000 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the transaction, the chief financial officer directly owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. This trade represents a 1.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 48,040 shares of company stock valued at $27,249,338. Corporate insiders own 5.70% of the company’s stock.

Institutional Trading of Axon Enterprise

A number of large investors have recently made changes to their positions in AXON. Westside Investment Management Inc. raised its position in shares of Axon Enterprise by 4.8% in the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 13 shares during the last quarter. CVA Family Office LLC raised its holdings in Axon Enterprise by 26.9% in the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 14 shares during the last quarter. Newbridge Financial Services Group Inc. lifted its stake in shares of Axon Enterprise by 2.8% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after purchasing an additional 14 shares during the period. Vicus Capital lifted its stake in shares of Axon Enterprise by 3.7% during the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 14 shares during the period. Finally, Evergreen Capital Management LLC boosted its holdings in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.